What do systematic reviews say?

Early vs deferred AST

Early probably leads to lower time to death of any cause (here: all‐cause mortality at 5 years) compared with deferred AST (moderate certainty).

• Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
  HR 0.82 [0.75, 0.9]
  10 studies · 4767 participants
  Moderate

Early vs deferred AST

Early showed no clear difference in serious adverse events compared with deferred AST (low certainty).

• Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
  RR 1.05 [0.95, 1.16]
  5 studies · 10575 participants
  Low

Early vs deferred AST

Early probably leads to lower time to death from prostate cancer (here: prostate cancer mortality… compared with deferred AST (moderate certainty).

• Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
  HR 0.69 [0.57, 0.84]
  7 studies · 3677 participants
  Moderate

Early vs deferred AST

Early may leads to lower skeletal events compared with deferred AST (low certainty).

• Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
  RR 0.37 [0.17, 0.8]
  3 studies · 2209 participants
  Low

Early vs deferred AST

Early may leads to higher fatigue compared with deferred AST (low certainty).

• Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
  RR 1.41 [1.23, 1.62]
  2 studies · 8209 participants
  Low

Early vs deferred AST

Early may leads to higher heart failure compared with deferred AST (low certainty).

• Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
  RR 1.9 [1.09, 3.33]
  1 study · 1214 participants
  Low

Early vs deferred AST

• Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 285 participants
  Moderate